OBJECTIVE： To observe clinical efficacy and safety of Bifidobacterium triple viable capsules in the adjunctive treatment of Helicobacter pylori （Hp） positive chronic atrophic gastritis （CAG） complicated with anxiety-depression. METHODS： A total of 100 Hp positive CAG patients with anxiety-depression were divided into control group and observation group according to random number table， with 50 cases in each group. Control group was given standard triple therapy （rabeprazole+amoxicillin and clavulanate+levofloxacin）. Observation group was additionally given Bifidobacterium triple viable capsules 0.42 g， tid. The treatment lasted for 14 d in both groups.  Clinical efficacies， Hp eradication rates as well as HAMA and HAMD scores before and after treatment were all observed in 2 group. The occurrence of ADR was compared. RESULTS： Total response rate of observation group was 94.0％， and Hp eradication rate was 92.0％， which were significantly higher than 76.0％ and 78.0％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in HAMA and HAMD scores in 2 groups （P＞0.05）. After treatment， HAMA and HAMD scores of 2 groups were decreased significantly， the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. The incidence of ADR in observation group （4.0％） was significantly lower than control group （20.0％）， with statistical significance （P＜0.05）. CONCLUSIONS： Adjunctive use of Bifidobacterium triple viable capsules can significantly improve Hp eradication rate， clinical symptom， anxiety and depression， while reduce the incidence of ADR.